PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9249578-7 1997 In IL-1 beta +/+ mice, IL-1ra inhibited production of IL-6 after zymosan, without affecting TNF-alpha synthesis. Zymosan 65-72 interleukin 6 Mus musculus 54-58 9212744-9 1997 Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels. Zymosan 0-7 interleukin 6 Mus musculus 51-55 10400825-0 1999 Role of interleukin-6 in a non-septic shock model induced by zymosan. Zymosan 61-68 interleukin 6 Mus musculus 8-21 10400825-10 1999 In vivo treatment with anti-IL-6 (5,000 ng/day per mouse, 24 and 1 hour before zymosan administration) significantly reduced the inflammatory process. Zymosan 79-86 interleukin 6 Mus musculus 28-32 10400825-11 1999 Taken together, the present study clearly demonstrates that IL-6 exerts a role in zymosan-induced non-septic shock. Zymosan 82-89 interleukin 6 Mus musculus 60-64 8674335-8 1996 Plasma TNF and IL-6 concentrations transiently increased during the first 24 hrs after administration of zymosan. Zymosan 105-112 interleukin 6 Mus musculus 15-19 2237286-0 1990 Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. Zymosan 64-71 interleukin 6 Mus musculus 45-58 2237286-3 1990 TNF and IL-6 release in mice treated with zymosan was investigated. Zymosan 42-49 interleukin 6 Mus musculus 8-12 2237286-10 1990 In contrast, maximal IL-6 release was reached upon stimulation with zymosan-activated serum only, while the presence of zymosan particles lowered this response. Zymosan 68-75 interleukin 6 Mus musculus 21-25 30075804-7 2018 RESULTS: OLT1177 reduced zymosan-induced joint swelling (p < 0.001), cell influx (p < 0.01), and synovial levels of interleukin (IL)-1beta, IL-6, and chemokine (C-X-C motif) ligand 1 (CXCL1) (p < 0.05), respectively, when compared with vehicle-treated mice. Zymosan 25-32 interleukin 6 Mus musculus 146-150 29527115-6 2018 The mRNA and protein expression levels of inflammatory cytokines (IL-1alpha, IL-6, IL-12, and IL-17) were also upregulated after zymosan stimulation. Zymosan 129-136 interleukin 6 Mus musculus 77-81 29411511-7 2018 Zymosan-A protected bone marrow cells from radiation-induced apoptosis, up-regulated IL-6, IL-12, G-CSF and GM-CSF in bone marrow cells. Zymosan 0-9 interleukin 6 Mus musculus 85-89 29411511-11 2018 Zymosan-A protected bone marrow cells from radiation-induced apoptosis and up-regulated IL-6, IL-12, G-CSF and GM-CSF. Zymosan 0-9 interleukin 6 Mus musculus 88-92 29881422-4 2018 The zymosan-mediated secretion of tumor necrosis factor-alpha (TNF)-alpha), interleukin (IL)-6), and IL12p40 but not IL-10 in BMDMs was significantly inhibited by pre-treatment with wedelolactone (30 microg/mL, P < 0.001). Zymosan 4-11 interleukin 6 Mus musculus 76-94 28922655-10 2017 Zymosan-A also promoted cell viability and inhibited cell apoptosis caused by radiation, induced radioprotective effects via TLR2, upregulated IL-6, IL-11, IL-12, and TNF-alpha in vivo. Zymosan 0-9 interleukin 6 Mus musculus 143-147 27619992-4 2016 Studies of PMN infiltration during zymosan-induced peritonitis reveal that hyperglycemia enhances PMN recruitment not through inducing a high level of IL-17, which is the case in colitis, but through increasing F4/80+ macrophages in the peritoneal cavity, resulting in elevations of IL-6, IL-1beta, TNF-alpha, and CXCL1 production. Zymosan 35-42 interleukin 6 Mus musculus 283-287 19721414-13 2009 IL-6 was by far the most induced acute-phase-cytokine in GD- and zymosan-treated livers, although IL-1beta and TNF-alpha were also strongly upregulated by zymosan and to a lesser extent by GD. Zymosan 65-72 interleukin 6 Mus musculus 0-4 23710113-3 2013 ISO dramatically attenuated ZY-induced lung neutrophil recruitment and inflammation, as evidenced by the reduced levels of total cells, neutrophils, and proinflammatory cytokines (i.e., tumor necrosis factor- alpha , interleukin- (IL-) 1 beta , IL-6, and macrophage inflammatory protein-2) in bronchoalveolar lavage fluid and of their mRNA expression in lung tissues. Zymosan 28-30 interleukin 6 Mus musculus 245-249 22712758-9 2012 Neutrophil migration and cytokine release (TNF-alpha, IL-1beta and IL-6) induced by zymosan and fluid leakage induced by acetic acid were also reduced in BS-treated animals. Zymosan 84-91 interleukin 6 Mus musculus 67-71 21703408-4 2011 In vitro, cytokine release from zymosan-stimulated macrophages was affected by AP214, with approximately 80%, 30%, and 40% reduction in IL-1beta, tumor necrosis factor-alpha, and IL-6, respectively. Zymosan 32-39 interleukin 6 Mus musculus 179-183 20618847-7 2010 The highest expression of IL-6, TLR2, and dectin-1 occurred when RAW264.7 cells were stimulated with zymosan and farnesol together. Zymosan 101-108 interleukin 6 Mus musculus 26-30 19733186-9 2009 KEY FINDINGS: Pre-treatment with C-K significantly inhibited zymosan-mediated secretion of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-12 p40, and the activation of ERK1/2 and p38. Zymosan 61-68 interleukin 6 Mus musculus 120-138 26949603-8 2016 It also inhibited the zymosan-induced up-regulation of IL-6, IL-8, and MCP-1 mRNA abundance in these cells. Zymosan 22-29 interleukin 6 Mus musculus 55-59 25654532-4 2015 pretreatment with gedunin (0.005-5 mg/kg) impaired zymosan-induced edema formation, neutrophil accumulation and hypernociception in mouse knee joints, due to decreased expression of preproET-1 mRNA and production of LTB4, PGE2, TNF-alpha and IL-6. Zymosan 51-58 interleukin 6 Mus musculus 242-246 23788175-6 2013 CH was able to counteract zymosan-induced ear-skin inflammation locally (ear swelling) as well as systemically (IL-6 production by lipopolysaccharide (LPS)-stimulated whole blood cells). Zymosan 26-33 interleukin 6 Mus musculus 112-116 21592365-11 2011 In vitro, trichostatin A markedly suppressed zymosan A-induced interleukin-12 and interleukin-6 production by BM-DC and up-regulated IDO expression at mRNA and protein levels. Zymosan 45-54 interleukin 6 Mus musculus 82-95 18656556-8 2008 The injection of zymosan resulted in a substantial increase in the serum level of TNF-alpha and IL-6, which was strongly inhibited by AG-490. Zymosan 17-24 interleukin 6 Mus musculus 96-100 18664788-12 2008 Interestingly, in mice treated with zymosan and phlebotomies, hepcidin expression was suppressed, despite the persistent increase in interleukin-6. Zymosan 36-43 interleukin 6 Mus musculus 133-146 16977380-6 2006 RESULTS: An intraperitoneal injection of zymosan A induced severe polyarthritis with increased levels of rheumatoid factor and interleukin 6 (IL-6) only in SKG mice. Zymosan 41-50 interleukin 6 Mus musculus 127-140 17363730-4 2007 The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF). Zymosan 43-50 interleukin 6 Mus musculus 161-174 17363730-4 2007 The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF). Zymosan 43-50 interleukin 6 Mus musculus 176-180 16977380-6 2006 RESULTS: An intraperitoneal injection of zymosan A induced severe polyarthritis with increased levels of rheumatoid factor and interleukin 6 (IL-6) only in SKG mice. Zymosan 41-50 interleukin 6 Mus musculus 142-146 16154177-4 2005 We found that LPS- and zymosan-stimulated TNF-alpha and IL-6 production is attenuated in splenic macrophages from aged mice compared to young. Zymosan 23-30 interleukin 6 Mus musculus 56-60 15188379-4 2004 METHODS: Zymosan was injected intraarticularly into naive wild-type (WT), IL-6(-/-), and STAT-1(-/-) mice to induce arthritis. Zymosan 9-16 interleukin 6 Mus musculus 74-78